+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neurofibromatoses Type II - Pipeline Review, H1 2020

  • ID: 5024697
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 44 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Beta Pharma Inc
  • BioXcel Corp
  • Plex Pharmaceuticals Inc
  • MORE
Neurofibromatoses Type II - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type II - Pipeline Review, H1 2020, provides an overview of the Neurofibromatoses Type II (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition. The signs and symptom are hearing loss, ringing in the ears (tinnitus), and problems with balance.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type II - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type II (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase 0 and Discovery stages are 3, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Neurofibromatoses Type II (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neurofibromatoses Type II (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neurofibromatoses Type II (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type II (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type II (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Beta Pharma Inc
  • BioXcel Corp
  • Plex Pharmaceuticals Inc
  • MORE
  • Introduction
  • Report Coverage
  • Neurofibromatoses Type II - Overview
  • Neurofibromatoses Type II - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Neurofibromatoses Type II - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neurofibromatoses Type II - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Beta Pharma Inc
  • BioXcel Corp
  • Plex Pharmaceuticals Inc
  • Recursion Pharmaceuticals Inc
  • Neurofibromatoses Type II - Drug Profiles
  • bortezomib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • icotinib hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • REC-2282 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • selumetinib sulfate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neurofibromatoses Type II - Dormant Projects
  • Neurofibromatoses Type II - Product Development Milestones
  • Featured News & Press Releases
  • May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Neurofibromatoses Type II, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Neurofibromatoses Type II - Pipeline by AstraZeneca Plc, H1 2020
  • Neurofibromatoses Type II - Pipeline by Beta Pharma Inc, H1 2020
  • Neurofibromatoses Type II - Pipeline by BioXcel Corp, H1 2020
  • Neurofibromatoses Type II - Pipeline by Plex Pharmaceuticals Inc, H1 2020
  • Neurofibromatoses Type II - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
  • Neurofibromatoses Type II - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Neurofibromatoses Type II, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca Plc
  • Beta Pharma Inc
  • BioXcel Corp
  • Plex Pharmaceuticals Inc
  • Recursion Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll